The strategy addresses several features of osteoporotic bone loss at once. Osteoporosis involves an imbalance in remodeling, in which bone resorption by osteoclasts can exceed new bone formation by osteoblasts. The condition is also associated with chronic low-grade inflammation and oxidative stress, while macrophages and other immune cells help determine the local inflammatory environment. The researchers therefore designed a delivery system intended to carry a gene-regulating cargo to relevant bone cells, reduce reactive oxygen species, and dampen inflammatory signaling. This was an experimental nanomedicine approach tested in cultured cells and a mouse model, not a clinical treatment.

For the gene-regulating component, the investigators used a miR-196b inhibitor. Previous evidence cited in the paper showed that miR-196b-5p can inhibit osteoblast differentiation and influence both osteogenic and osteoclastic processes, including signaling associated with Sema3a, Wnt/β-catenin and the RANKL/OPG system. In the engineered particles, the inhibitor increased expression of GATA6, a downstream target used to verify miR-196 inhibition. M2 macrophage-derived exosomes were selected as the carrier because they provide an extracellular-vesicle delivery platform with reported immunomodulatory and osteogenic properties. Platinum nanoparticles were added for their enzyme-like antioxidant activity. The system was thus designed to combine RNA regulation, reactive oxygen species scavenging and alteration of the local osteoimmune environment in a single carrier.

The researchers characterized the engineered vesicles using transmission electron microscopy, nanoparticle tracking analysis, Western blotting and cell-viability assays. The M2-derived exosomes had a typical cup-shaped structure and an average diameter of 118.0 ± 43.9 nm, while the targeted, co-loaded formulation measured 139.2 ± 48.8 nm. Electron microscopy indicated that loading and targeting modifications did not visibly disrupt the vesicular membrane or cause obvious aggregation. HSP90, TSG101 and CD9 were detected as exosomal markers. No significant cytotoxicity was observed after 24 or 72 hours in the tested cell systems. Platinum-containing formulations showed stronger scavenging activity for hydrogen peroxide, hydroxyl radicals and superoxide than unmodified exosomes or blank controls, supporting the intended redox-buffering function of the nanoparticles.

Targeting was tested both in cultured cells and in mice. The SDSSD peptide was selected because it binds periostin, a ligand associated with osteoblast targeting. Confocal microscopy showed that BT-modified exosomes were taken up preferentially by MC3T3-E1 osteoblast-lineage cells compared with RAW264.7 macrophages. After intravenous administration of fluorescently labeled particles, BT-Exos accumulated more strongly in femur sections than unmodified exosomes. Ex vivo imaging of the brain, heart, liver, spleen, lungs, kidneys, tibiae and femora likewise showed stronger skeletal fluorescence and reduced distribution in other organs for the targeted formulation. The authors interpret these findings as evidence of preferential bone accumulation, although the experiments did not establish the complete fate of the particles or the precise cellular route of uptake. The delivery advantage was therefore demonstrated under the study’s experimental conditions rather than as a general property of all exosome formulations.

In inflammatory cell assays, the components produced complementary effects. Platinum-containing formulations showed the greatest intracellular ROS-scavenging performance, while M2-derived exosomes reduced the expression of the pro-inflammatory cytokines interleukin-1β, interleukin-6 and tumor necrosis factor-alpha. Combining the exosome, platinum and miR-196 inhibitor produced the strongest overall reductions in cytokine expression, with quantitative reverse-transcription PCR agreeing with the fluorescence measurements. Comparisons of exosomes from M0, M1 and M2 macrophages also showed that M1 and M2 exosomes increased alkaline phosphatase activity and mineralization relative to controls, but only M2 exosomes significantly increased RUNX2 expression, the osteogenic transcription factor used by the researchers to justify the choice of carrier. These results support the rationale for using M2-derived vesicles, while not establishing that the formulation will produce the same effects in human bone tissue.

The targeted particles promoted osteoblast development in vitro. After seven days of osteogenic induction, the fully engineered formulation produced the strongest alkaline phosphatase staining; after 14 days, treated cultures showed greater calcium deposition by Alizarin Red S staining than controls. Western blotting showed progressively higher RUNX2 and ALP protein levels across the treatment groups, with BT-Exo-Pt-miR-196 inhibitor highest among them. Immunofluorescence measurements of osterix and osteocalcin followed the same pattern. Quantitative proteomics of MC3T3-E1 cells treated with BT-Exo-miR-196 inhibitor identified 605 up-regulated and 531 down-regulated proteins relative to control, with six biological replicates per group. Increased proteins included SP7, LRP5 and RUNX2, together with matrix-related proteins POSTN, BGN and LOX, while innate immune and cytokine-associated proteins including TBK1, P2RX7, C3, CGAS, TLR2, PTGS2 and ISG15 decreased. Pathway enrichment indicated changes involving mitochondrial and respiratory-chain proteins, extracellular matrix processes and immune signaling. These measurements are cellular and biochemical observations, not evidence of fracture healing in people.

Osteoclast formation was also reduced in laboratory cultures. Bone-marrow-derived macrophages exposed to osteoclast-inducing conditions developed fewer TRAP-positive multinucleated cells after treatment with the engineered formulations, and the untargeted co-loaded exosome produced the lowest osteoclastogenesis in that assay. Phalloidin staining showed weaker F-actin ring formation, while Western blot and gene-expression measurements showed lower levels of osteoclast-associated markers, including NFATc1, cathepsin K, MMP9 and TRAP. The untargeted result was not considered a contradiction: the SDSSD peptide binds periostin on osteoblasts and was not designed to bind osteoclast precursors. Its benefit in the animal model was therefore interpreted as preferential delivery to bone surfaces and remodeling regions rather than direct targeting of osteoclasts. In other words, the targeting strategy appeared useful for concentrating the therapy in the bone microenvironment, but the osteoclast cultures did not provide evidence that the peptide directly targets osteoclasts.

In the in vivo experiment, eight-week-old female C57BL/6 mice were assigned to sham-operated, ovariectomized, untargeted-treatment and targeted-treatment groups, with five animals per group. Treatments began two weeks after surgery and involved tail-vein injections every three days for six weeks. Each treatment dose contained 100 μL of PBS with 1.0 × 10^11 particles/mL, and the ovariectomy-only group received PBS on the same schedule. Micro-CT of the distal femur showed that ovariectomy reduced bone mineral density and trabecular bone volume fraction, increased trabecular separation and reduced trabecular thickness and number. Both nanoparticle treatments partially reversed these changes, but the targeted formulation produced the most pronounced preservation of trabecular architecture. H&E and Masson trichrome staining supported the imaging results by showing improved trabecular organization and matrix deposition. TRAP staining showed the least osteoclast-positive area after targeted treatment, while osteocalcin and osterix measurements indicated stronger osteogenic activity and cathepsin K staining indicated reduced osteoclast-associated activity. The experiment therefore showed improved preservation of bone structure and remodeling markers in this model, rather than complete restoration of a healthy skeleton or prevention of fractures.

The study also reported an initial biosafety signal. White blood cell, red blood cell and platelet counts did not differ significantly among the groups. Serum ALT, AST, blood urea nitrogen and creatinine remained within the reported ranges, and histological examination of the heart, liver, spleen, lungs and kidneys showed no obvious inflammatory infiltration, necrosis or structural damage. These findings support short-term tolerability in this mouse model, but they are not a comprehensive translational safety assessment. The exosomes are cell-derived biological products with possible batch variability, immunogenicity and manufacturing challenges, while the platinum nanoparticles are not enzymatically degraded and may persist in internal organs. Longer observation, dose-escalation studies, quantitative clearance analysis and tests for anti-exosome immune responses remain necessary. Overall, the findings identify an experimental strategy for coordinating bone formation, osteoclast suppression, oxidative-stress control and inflammatory modulation, but its efficacy and safety in humans remain untested.

Subject of Research: Experimental bone-targeted exosome delivery for ovariectomy-induced osteoporosis in mice

Article Title: Engineering exosomes-mediated RNA delivery regulates bone homeostasis and alleviates osteoporosis

Article References: Du, Y., Zhang, Y., Wang, Z., Jiang, H., Li, L., Liu, X., Zhou, P., Huang, X., Liu, J., Li, Z., & Li, Z. (2026). Engineering exosomes-mediated RNA delivery regulates bone homeostasis and alleviates osteoporosis. Materials Today Bio, 41, Article 103758. https://doi.org/10.1016/j.mtbio.2026.103758

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103758

Keywords: osteoporosis, exosomes, miR-196b inhibition, bone targeting, platinum nanoparticles, osteogenesis, osteoclastogenesis, oxidative stress, nanomedicine, mouse model, Engineering, exosomes-mediated